Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer

  • Technology appraisal guidance
  • TA192
  • Published: 
Download guidance (PDF)

1 Guidance

1.1 Gefitinib is recommended as an option for the first-line treatment of people with locally advanced or metastatic non-small-cell lung cancer (NSCLC) if:

  • they test positive for the epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation and

  • the manufacturer provides gefitinib at the fixed price agreed under the patient access scheme.

  • National Institute for Health and Care Excellence (NICE)